MYO5B and neoplasm: Through these combined actions, LRP5-activated osteocytes, via LIMA1 and MYO5B, simultaneously suppress tumor growth, limit osteolysis, and alleviate the immunosuppressive milieu within the bone metastatic niche [35,36].